Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 2468.

https://doi.org/10.1182/blood.V126.23.2468.2468

Published: 2015

Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3695.

https://doi.org/10.1182/blood.V126.23.3695.3695

Published: 2015

Journal Articles

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Robert Collins, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jenny Chen, MDPhD, Meghan Macaraeg, BS, Vinoo Urity, MS, Blake Pond, MS, Abhijit Ramachandran, MS, Jorge E. Cortes, MD

Blood (2015) 126 (23): 4359.

https://doi.org/10.1182/blood.V126.23.4359.4359

Published: 2015

Journal Articles

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Philip Alastair Thompson, MBBS,FRCPA,FRACP, Maria Konopleva, MD PhD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Zeev Estrov, MD, Abhijit Ramachandran, PhD, Jamil Paradela, Michael Andreef, MD PhD, Mark Levis, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 389.

https://doi.org/10.1182/blood.V124.21.389.389

Published: 2014

Journal Articles

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Marcus M Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Julia Frey, Katja Schuster, PhD, Abhijit Ramachandran, Lothar Kanz, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2014) 124 (21): 2230.

https://doi.org/10.1182/blood.V124.21.2230.2230

Published: 2014

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Jolieke G van Oosterwijk, PhD, Eric I Zimmerman, PhD, Yong-Dong Wang, PhD, Shelley Orwick, Aksana Vasilyeva, PhD, Katja Schuster, PhD, Abhijit Ramachandran, PhD, Hiroto Inaba, MD PhD, Sharyn D Baker, PharmD, PhD

Blood (2014) 124 (21): 3620.

https://doi.org/10.1182/blood.V124.21.3620.3620

Published: 2014

Journal Articles

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge Cortes, Mark Levis

Blood (2014) 123 (1): 94–100.

https://doi.org/10.1182/blood-2013-10-529313

Published: 2014

Includes: Supplemental data

Journal Articles

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

Eric I. Zimmerman, David C. Turner, Jassada Buaboonnam, Shuiying Hu, Shelley Orwick, Michael S. Roberts, Laura J. Janke, Abhijit Ramachandran, Clinton F. Stewart, Hiroto Inaba, Sharyn D. Baker

Blood (2013) 122 (22): 3607–3615.

https://doi.org/10.1182/blood-2013-07-513044

Published: 2013

Includes: Supplemental data

Journal Articles

Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations

Chen Gao, Weiguo Zhang, M.D., Ph.D., Rodrigo Jacamo, Ph.D, Abhijit Ramachandran, Donald Small, MD, PhD, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 3591.

https://doi.org/10.1182/blood.V120.21.3591.3591

Published: 2012

Journal Articles

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations

Allison Galanis, Trivikram Rajkhowa, Chaitanya Muralidhara, Abhijit Ramachandran, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 1341.

https://doi.org/10.1182/blood.V120.21.1341.1341

Published: 2012

NARROW

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only